An Overview of the Genomic Characterization of Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yim, Sun Young | - |
dc.contributor.author | Lee, Ju-Seog | - |
dc.date.accessioned | 2022-03-12T06:40:20Z | - |
dc.date.available | 2022-03-12T06:40:20Z | - |
dc.date.created | 2022-01-20 | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 2253-5969 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/138694 | - |
dc.description.abstract | Tumor classifications based on alterations in the genome, epigenome, or proteome have revealed distinct tumor subgroups that are associated with clinical outcomes. Several landmark studies have demonstrated that such classifications can significantly improve patient outcomes by enabling tailoring of therapy to specific alterations in cancer cells. Since cancer cells accumulate numerous alterations in many cancer-related genes, it is a daunting task to find and confirm important cancer-promoting alterations as therapeutic targets or biomarkers that can predict clinical outcomes such as survival and response to treatments. To aid further advances, we provide here an overview of the current understanding of molecular and genomic subtypes of hepatocellular carcinoma (HCC). System level integration of data from multiple studies and development of new technical platforms for analyzing patient samples hold great promise for the discovery of new targets for treatment and correlated biomarkers, leading to personalized medicine for treatment of HCC patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | DOVE MEDICAL PRESS LTD | - |
dc.subject | TERT PROMOTER MUTATIONS | - |
dc.subject | GENE-EXPRESSION SIGNATURE | - |
dc.subject | CATALYTIC SUBUNIT HTERT | - |
dc.subject | TELOMERASE ACTIVITY | - |
dc.subject | ARID1A MUTATIONS | - |
dc.subject | EARLY RECURRENCE | - |
dc.subject | CANCER-CELLS | - |
dc.subject | MUTANT P53 | - |
dc.subject | NRF2 | - |
dc.subject | PREDICTION | - |
dc.title | An Overview of the Genomic Characterization of Hepatocellular Carcinoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yim, Sun Young | - |
dc.identifier.doi | 10.2147/JHC.S270533 | - |
dc.identifier.wosid | 000694806100001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF HEPATOCELLULAR CARCINOMA, v.8, pp.1077 - 1088 | - |
dc.relation.isPartOf | JOURNAL OF HEPATOCELLULAR CARCINOMA | - |
dc.citation.title | JOURNAL OF HEPATOCELLULAR CARCINOMA | - |
dc.citation.volume | 8 | - |
dc.citation.startPage | 1077 | - |
dc.citation.endPage | 1088 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | TERT PROMOTER MUTATIONS | - |
dc.subject.keywordPlus | GENE-EXPRESSION SIGNATURE | - |
dc.subject.keywordPlus | CATALYTIC SUBUNIT HTERT | - |
dc.subject.keywordPlus | TELOMERASE ACTIVITY | - |
dc.subject.keywordPlus | ARID1A MUTATIONS | - |
dc.subject.keywordPlus | EARLY RECURRENCE | - |
dc.subject.keywordPlus | CANCER-CELLS | - |
dc.subject.keywordPlus | MUTANT P53 | - |
dc.subject.keywordPlus | NRF2 | - |
dc.subject.keywordPlus | PREDICTION | - |
dc.subject.keywordAuthor | gene expression profile | - |
dc.subject.keywordAuthor | RNA-seq | - |
dc.subject.keywordAuthor | proteomics | - |
dc.subject.keywordAuthor | mutations | - |
dc.subject.keywordAuthor | genomic subtypes | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.